Abstract:
The present invention relates to an Aß(X - 38.. 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the Aß(X - 38.. 43) oligomer or derivative. The subject invention also describes agents that are capable of binding to the Aß(X - 38.. 43) oligomer or derivative, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis.
Abstract:
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
Abstract:
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
Abstract:
Die vorliegende Erfindung betrifft neuromodulierende Oligomere des Amyloid-β(1-42)-Proteins, ein spezielles Herstellungsverfahren, mit dem die Oligomere in reproduzierbarer Weise und grosser Ausbeute erhältlich sind, sowie die Verwendung der Oligomere als Diagnostika und Therapeutika, zur Erzeugung oligomerspezifischer Antikörper und zum Auffinden von Substanzen, die mit den Oligomeren und deren Bildung in Wechselwirkung treten können. Entsprechende Verfahren zur Erzeugung der Antikörper bzw. zum Auffinden der Substanzen werden genauso beschrieben wie die die Antikörper selbst und die Verwendung der Antikörper bzw. Substanzen als Diagnostika und Therapeutika. Die Erfindung betrifft in gleicher Weise auch Derivate der Oligomere, insbesondere quervernetzte Oligomere und Oligomere auf Basis verkürzte Formen des Amyloid-β(1-42)-Proteins davon, deren Herstellung und deren Verwendung.
Abstract:
The present invention relates to amyloid-beta (As) binding proteins. Antibodies of the invention have high affinity to As(20-42) globulomer or any Aƒ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
Abstract:
The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
Abstract:
Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-Aβ globulomer antibodies having a binding affinity to Aβ(20-42) globulomer that is greater than the binding affinity of the antibody to Aβ(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
Abstract:
Anti-Aß globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-Aß globulomer antibodies having a binding affinity to Aß(20-42) globulomer that is greater than the binding affinity of the antibody to Aß(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
Abstract:
The present invention is relates to non-diffusible globular Aß(X - 38 .. 43) oligomers ("globulomers") or derivatives thereof, methods for enriching said globulomers or derivatives, compositions comprising said globulomers or derivatives, antibodies and aptamers having specificity for said globulomers or derivatives, methods for preparing such antibodies and aptamers, uses of said globulomers or derivatives, or of said antibodies or aptamers for diagnostic, therapeutic and other purposes, and corresponding methods using said globulomers or derivatives, or said antibodies or aptamers.
Abstract:
The present invention is relates to non-diffusible globular Aβ(X - 38 .. 43) oligomers ("globulomers") or derivatives thereof, methods for enriching said globulomers or derivatives, compositions comprising said globulomers or derivatives, antibodies and aptamers having specificity for said globulomers or derivatives, methods for preparing such antibodies and aptamers, uses of said globulomers or derivatives, or of said antibodies or aptamers for diagnostic, therapeutic and other purposes, and corresponding methods using said globulomers or derivatives, or said antibodies or aptamers.